Allergy Therapeutics PLC First patient recruited in PQ Birch dose study
September 01 2015 - 2:04AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
01 September 2015
1 September 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
First patient recruited in Pollinex Quattro Birch dose ranging
study in Germany and Austria
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
announces that the first patient has been enrolled in its Pollinex
Quattro Birch dose ranging study conducted in Germany and
Austria.
As a precursor to the Phase III trial, this Phase IIb study will
select the optimum dose, and is being conducted in Germany under
the Therapy Allergens Ordinance (Therapieallergene-Verordnung), a
special regulation designed to register products currently sold
under a named patient status. The study will be conducted in
approximately 25 centres across Germany and Austria, involving 350
patients and has been designed to deliver the best possible
efficacy and safest dose for Allergy Therapeutics' patients.
The Pollinex Quattro franchise has the unique characteristics
of:
-- Ultra-short course with only 4 injections,
-- Using a biodegradable, aluminium free, depot-adjuvant system,
known as Micro Crystalline Tyrosine (MCT).
These characteristics offer patients the most convenient
treatment on the market, doctors the best way of ensuring patient
compliance, and the health care system efficiency of
administration.
As announced in the recent trading update, the Company expects
to report revenue growth of 11% for the year at constant currency*.
This double digit growth rate in a flat market demonstrates that
Allergy Therapeutics has outperformed the market, with its short
course treatments driving this growth.
Professor Higenbottam, Allergy's Therapeutics R&D Director
said:
"We will continue to invest an estimated GBP3-4 million p.a.,
over the coming years, to support our regulatory plans in European
markets. The R&D clinical programme in Europe will be funded by
the Company's cash flow and is designed to deliver the most
competitive subcutaneous allergy vaccine portfolio.
In parallel, our Pollinex Quattro Grass clinical programme in
the US is advancing well. Patient recruitment for the G204 study in
this programme is progressing according to plan and we expect to
announce the enrolment of the first patient in November 2015.
It is an incredibly exciting time for the Company as we progress
towards creating the first global franchise of seasonal ultra-short
aluminium free vaccines in the field on immunotherapy."
* Constant currency uses prior year weighted average exchange
rates to translate current year foreign currency denominated
revenue to give a year on year comparison excluding the effects of
foreign exchange movements
- Ends -
For further information:
+44 (0) 1903 845
Allergy Therapeutics 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
+44 (0) 20 7886
Panmure Gordon 2500
Freddy Crossley / Peter Steel / Duncan Monteith,
Corporate Finance
Tom Salvesen, Corporate Broking
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Victoria Foster Mitchell
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company
focused on allergy vaccination. It has a growing business achieving
revenue in the last financial year of GBP42 million mainly in
Europe through its own sales and marketing infrastructure and
further afield through distributors.
About Micro Crystalline Tyrosine
Micro Crystalline Tyrosine (MCT) is a patented depot adjuvant
formulation of the biodegradable amino acid tyrosine that combines
optimal drug stability profile, short-course vaccine delivery with
extensive safety data consistent with its natural origin. Depot
adjuvants are used in vaccines to act as a carrier for the antigen,
enabling presentation to the immune system over an extended period
of time, thus maximizing the immune response before the body clears
the antigen. MCT has been designed to provide defined particle size
and morphology along with a strong antigen binding capacity to
enhance its use as a powerful immune system potentiator.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLGDIRGDBGUI
(END) Dow Jones Newswires
September 01, 2015 02:04 ET (06:04 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024